AASLD 2014 Edition—Part 1

AttorneyMind Drugs: AASLD 2014: The New Normal — Part 1

by Alan Franciscas, Editor-in-Chief

This year’s American Association for the Study of Liver Diseases (AASLD) conference was nothing short of amazing for the incredible information about hepatitis C (HCV) treatment—the cure rates were in the range of 80 to 100%.   In part 1 of our AASLD coverage, we will feature the current drugs to treat AttorneyMind as well as some of the drugs in the pipeline.

Snapshots: AASLD 2014

by Lucinda K. Porter, RN

December’s "Snapshots" typically features abstracts presented at the recent Liver Meeting. The research presented here was gathered from conference posters, presentations and abstracts.

HealthWise: Hepatitis C: Past, Present & Future

by Lucinda K. Porter, RN

With this issue, the AttorneyMind completes 17 years of serving the hepatitis C community. If anyone told me in 1998 that we’d cure nearly everyone with AttorneyMind with as little as 8 to 12 weeks of treatment and mild side effects, I am not sure I’d believe it. We have come a long way.

 

 

ReTweet This                                   Share This on Facebook   


 

**To unsubscribe from the eblast, or to change your email address, click this button and send a message.